Print

Cytheris SA, Centre Léon Bérard and ImmunID Announce Initiation of Clinical Trial to Evaluate Combination Regimen of IL-7 (CYT107) and XELODA(R) (capecitabine) in Treatment of Metastatic Breast Cancer  
5/11/2011 8:57:44 AM

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, the Centre Léon Bérard (Lyon), the major cancer research and treatment center for the Rhône-Alpes region of France, and ImmunID Technologies SAS (Grenoble), a diagnostic company specialized in innovative immunomonitoring tests and services, today announced initiation of a Phase IIa clinical trial that will evaluate multiple combinations of recombinant human interleukin-7 (CYT107), the investigational multifunctional cytokine under development by Cytheris, and a chemotherapeutic agent, XELODA® (capecitabine, Roche/Genentech), in the treatment of metastatic breast cancer.
//-->